2018
DOI: 10.1016/j.ajps.2017.09.001
|View full text |Cite
|
Sign up to set email alerts
|

Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

4
69
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 167 publications
(73 citation statements)
references
References 30 publications
4
69
0
Order By: Relevance
“…In addition, Liu et al [ 116 ] prepared nanoparticles of carboxymethyl chitosan for the release of intra-nasal carbamazepine (CBZ) to bypass the blood–brain barrier membrane, thus increasing the amount of the medication in the brain and refining the treatment efficacy, thereby reducing the systemic drug exposure. The nanoparticles had a mean diameter of 218.76 ± 2.41 nm, encapsulation efficiency of 80% and drug loading of 35%.…”
Section: Drug Designing and Drug Delivery Process And Mechanismmentioning
confidence: 99%
“…In addition, Liu et al [ 116 ] prepared nanoparticles of carboxymethyl chitosan for the release of intra-nasal carbamazepine (CBZ) to bypass the blood–brain barrier membrane, thus increasing the amount of the medication in the brain and refining the treatment efficacy, thereby reducing the systemic drug exposure. The nanoparticles had a mean diameter of 218.76 ± 2.41 nm, encapsulation efficiency of 80% and drug loading of 35%.…”
Section: Drug Designing and Drug Delivery Process And Mechanismmentioning
confidence: 99%
“…There are several mechanisms which govern drug release from chitosan nanoparticles such as: swelling of the polymer [25], diffusion of the adsorbed drug, drug diffusion through the polymeric matrix, polymer erosion or degradation and a combination of both erosion and degradation [26] as represented in Figure 3. The initial burst release from the chitosan nanoparticles is either because of swelling of the polymer, creating pores, or diffusion of the drug from the surface of the polymer [27].…”
Section: Drug Release From Chitosan Nanoparticlesmentioning
confidence: 99%
“…Carboxymethyl chitosan NPs of carbamazepine have found to enhance the bioavailability and brain targeting via the nasal route. The brain-to-plasma exposure ratio was 150% when carbamazepine was administered as chitosan NPs intranasally [25]. In Alzheimer’s disease (AD), a person’s sex is a risk factor and in women with AD, the levels of 17β-estradiol are found to be relatively low.…”
Section: Chitosan In Nasal Drug Deliverymentioning
confidence: 99%
“…Other factors that influenced the high brain uptake of the drug are the use of mucoadhesive material in the formulation which extended the contact time of the formulation in the nasal mucosa. The encapsulation of drug into the nanoparticles enhanced the drug bioavailability and brain targeting by adhering to the mucosal surface, thereby improving the drug dissolution in the mucosa [76].…”
Section: Nanoparticles (Nps)mentioning
confidence: 99%